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Ab initio 3 dimensional structural modeling
Docking conformationThe phospholipase D (PLD) superfamily catalyzes the hydrolysis of cell membrane phospholipids generating the
key intracellular lipid second messenger phosphatidic acid. However, there is not yet any resolved structure
either from a crystallized protein or from NMR of any mammalian PLDs. We propose here a 3D model of the
PLD2 by combining homology and ab initio 3 dimensional structural modeling methods, and docking conforma-
tion. This model is in agreement with the biochemical and physiological behavior of PLD in cells. For the lipase
activity, the N- and C-terminal histidines of the HKDmotifs (His 442/His 756) form a catalytic pocket, which ac-
commodates phosphatidylcholine head group (but not phosphatidylethanolamine or phosphatidyl serine). The
model explains themechanism of the reaction catalysis, with nucleophilic attacks of His 442 andwater, the latter
aided by His 756. Further, the secondary structure regions superimposed with bacterial PLD crystal structure,
which indicated an agreement with the model. It also explains protein–protein interactions, such as PLD2–
Rac2 transmodulation (with a 1:2 stoichiometry) and PLD2 GEF activity both relevant for cell migration, as
well as the existence of binding sites for phosphoinositides such as PIP2. These consist of R236/W238 and
R557/W563 and a novel PIP2 binding site in the PH domain of PLD2, speciﬁcally R210/R212/W233. In each of
these, the polar inositol ring is oriented towards the basic amino acid Arginine. Since tumor-aggravating proper-
ties have been found in mice overexpressing PLD2 enzyme, the 3D model of PLD2 will be also useful, to a large
extent, in developing pharmaceuticals to modulate its in vivo activity.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
PLDhas been associatedwith a variety of physiological cellular func-
tions, such as intracellular protein trafﬁcking, cytoskeletal dynamics,
membrane remodeling and cell proliferation [1,2] andwith pathological
activities such as angiogenesis and tumorigenesis [3,4]. There are
currently 6 mammalian isoforms of the gene (PLD1, 2, 3, 4, 5 and
6) [5–8]. Out of these, PLD1 has been extensively studied. The PLD1
gene has been localized to the long arm (q) of chromosome 3 (3q26)
[9] and covers 210 kb of genomic DNA that is deﬁned by 31 exons
[10,11]. The mammalian PLD2 gene is found on the short arm (p) of
chromosome 17 (17p13) [12], is deﬁned by 25 known exons of a
genomic region spanning 16.3 kb and encodes for two splice variants
(PLD2a and PLD2b) of 933 amino-acids in length each [13], which yields
functionally indistinguishable proteins of 106 kDa MW [14].
All members of the PLD superfamily possess two highly conserved
phosphatidyltransferase HKD catalytic domains (HKD1 and HKD2)hool Medicine, Department of
n Highway, Dayton, OH 45435,
ez-Cambronero).
. This is an open access article underthat are deﬁned by the consensus peptide sequence HxK(x)4D(x)
6GSxN, which are vital to the lipase activity. PLD1 and PLD2 also bear
the phox homology (PX) and pleckstrin homology (PH) domains, both
at the N-terminal end and the phosphatidylinositol 4,5-bisphosphate
[PIP2] binding site [15]. Two HKDmotifs are requisite for catalytic activ-
ity [16]. In the case of salmonella endonuclease (nuc) the protein forms
dimer to catalyze the reaction. In higher organisms the protein contains
two HKD motifs suggesting a duplication and common origin. In
these proteins, both the motifs tightly interact to form an active cen-
ter [16,17]. The HKDmotifs are also present in other biologically diverse
proteins such as bacterial phospholipid synthases, endonucleases, a pox
envelope protein and a Yersinia toxin.
PLD1 and PLD2 are classical mammalian PLD isoforms [15]. The PX
and PH domains of PLD1 and PLD2 function as strong modulators of
the membrane recycling machinery. It regulates, for example, interac-
tion with SH2/SH3-containing tyrosine kinases [18,19]. PLD3, PLD4,
PLD5 and PLD6 isoforms lack PX and PH domains [20] and, therefore,
could be considered non-classical PLDs.
Apart from lipase activity, PLD2 possesses guanine nucleotide ex-
change activity (GEF) for the small GTPase Rac2 and Ras [21–23]. The
PX domain of PLD2 contains the site for GEF activity, whereas both the
PLD2-PX and -PH domains are involved in interacting with the small
GTPase substrate [24], which can be either Rac2 or Ras [22,25].the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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yet any resolved structures of the protein either from a crystallized pro-
tein or from NMR. Therefore, we set out to model the isoform of PLD2,
using computational methods and selecting from among the candidate
structures on the basis of their consistencywith the experimental results.
We report here a 3Dmodel of PLD2, fully based on biochemical data,
which will help explain the 2 intermolecular enzymatic activities, as
well as to reasonably predict the physiological behavior of PLD in cells,
protein–protein interactions and phospholipid binding sites.
Having a working modeled structure of PLD will tremendously help
in the rational design of more speciﬁc inhibitors that are proving to
become quite important for recovering tumorigenesis [26], as relates
to the PLD/phospholipid ﬁelds.
2. Experimental procedures
2.1. Reagents
Dulbecco's modiﬁed Eagle's medium (DMEM) was from Mediatech
(Manassas, VA); Opti-MEM, Lipofectamine, Plus reagent, and Lipofecta-
mine 2000 were from Invitrogen (Carlsbad, CA); [3H]butanol was from
American Radiolabeled Chemicals (St. Louis, MO); [35S] GTPγSwas from
Perkin-Elmer (Waltham, MA); ECL reagent was from GE Healthcare
(Piscataway, NJ). The plasmids used in this experiment were as fol-
lows: pcDNA3.1-mycPLD2-WT, pcDNA3.1-mycPLD2-K758R, pcDNA3.1-
mycPLD2-F129Y, pcDNA3.1-mycPLD2-R172C, pcDNA3.1-mycPLD2-
D263-266, pRK5-myc-Rac2 or pCMV6-mycHRas, mCit-C1(pEYFP-C1)-
YFP-PLD2 and pCerulean-C1-PLD2.
2.2. Cells and cell culture
COS-7 cells were obtained from the American Type Culture Collec-
tion. Cells were cultured in DMEM supplemented with 10% (v/v) fetal
bovine serum (FBS).
2.3. Transfections
Transfections were performed using appropriate amounts of plas-
mid DNA, 5 μl Lipofectamine (Invitrogen), and 5 μl Plus reagent
(Invitrogen) in Opti-MEMmedium (Invitrogen), per themanufacturer's
protocol. COS-7 cells or RAW264.7/LR5 macrophages were transfected
for 3 h, washed, re-fed with prewarmed complete medium, and main-
tained for 48 h. After 48 h, cells were harvested for their respective ex-
periment. When necessary, post-transfection before harvesting, cells
were treated with 10 nM EGF or IL-8 depending upon the experiment
and the cell line for indicated time lengths.
2.4. Puriﬁcation of PLD2 and Rac2 using baculoviral expression system
To generate a puriﬁed, recombinant, and full-length PLD2 or Rac2, a
baculovirus expression system was used for the overexpression and
subsequent puriﬁcation. Brieﬂy, the PLD2-WT or Rac2-WT genes and
the Bsu36I-digested BacPAK5 viral DNA were co-transfected into Sf21
insect cells in separate reactions, which rescued the very large viral
DNA and effectively transferred the PLD2 or the Rac2 genes separately
into the AcMNPV genome. PLD2 or Rac2 baculoviral stocks were select-
ed that overexpressed PLD2-WT or Rac2, respectively, andwere used to
infect Sf21 insect cells for further overexpression of PLD2 or Rac2 and
subsequent puriﬁcations of PLD2 or Rac2 using the TALON matrix, as
previously described in [27].
2.5. Immunoprecipitation, SDS-PAGE and western blot analyses
After transfection, cells were harvested and lysed with special lysis
buffer (5 mM HEPES, pH 7.8, 100 μM sodium orthovanadate, and
0.1% Triton X-100). The lysates were sonicated and the presence ofoverexpressed protein was conﬁrmed by performing SDS-PAGE and
Western blot analysis. For immunoprecipitation, the cell lysates were
treated with 1 μl monoclonal antibody for the respective protein and
10 μl agarose beads (Millipore, Billerica, MA) and incubated at 4 °C for
4 h. After incubation, the immunoprecipitates were washed with LiCl
wash buffer (2.1% LiCl, 1.6% Tris–HCl, pH 7.4) and NaCl wash buffer
(0.6% NaCl, 0.16% Tris–HCl, 0.03% EDTA, pH 7.4), respectively, and
sedimented at 12,000 ×g for 1 min. The resulting pellets were then
analyzed using SDS-PAGE and Western blot (WB) analyses.
2.6. Lipase assay
Phospholipase D activity (transphosphatidylation) in cell sonicates
was measured using short chain PC, 1,2-dioctanoyl-sn-glycero-3-
phosphocholine (PC8) micelles or 1,2-diarachidonoyl-sn-glycero-3
phosphocholine (AraPC) or 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) liposomes and [3H] butanol. In the case of long chain fatty acid
containing PC, the liposomes were sonicated to form SUVs. Approxi-
mately 50 μl of cell sonicates was added to microcentrifuge Eppendorf
tubes containing the following assay mix (120 μl ﬁnal volume):
3.5 mM PC8 or DOPC or AraPC, 1 mM PIP2, 75 mM HEPES, pH 7.9, and
2.3 μCi (4 mM) of [3H]butanol. The mixture was incubated for 20 min
at 30 °C, and the reactionwas stopped by adding 300 μl of ice-cold chlo-
roform/methanol (1:2). Lipids were extracted and dried for thin layer
chromatography (TLC). TLC lanes that migrated as authentic phospho
butanol were scraped, dissolved in 3 ml of Scintiverse II scintillation
mixture, and counted. Background counts (boiled samples) were
subtracted from experimental samples.
2.7. GEF activity: GTP binding
GTP ([35S]-GTPgS) binding of Rac2 or Ras wasmeasured in the pres-
ence of immunoprecipitated PLD2-WT or PLD2-F129Y or PLD2-R172C.
Recombinant PLD2-WT was used as the positive. Nineteen pmol of
Rac2 was incubated with 8 μM GDP, 6 mM MgCl2 (20 μl volume) for
10 min at room temp. GDP-bound Rac2 was added to 20 μl 100 mM
AMP-PNP, 1 mM MgCl2 and 1 μM [35S]-GTPgS in the absence or pres-
ence of recombinant PLD2 or immunoprecipitated PLD2-WT or F129Y
or R172C (45 μl volume). The relative amount of GTPgS-bound to Rac2
was measured by scintillation spectrometry.
2.8. Coimmunoprecipitation analyses
After transfection, cells were harvested and lysed with Special lysis
buffer (5 mM HEPES, pH 7.8, 100 mM sodium orthovanadate, and 0.1%
Triton X-100). The lysates were sonicated and treated with 1 ml mono-
clonal antibody for the respective protein and 10 ml agarose beads
(Millipore, Billerica, MA) and incubated at 4 °C overnight. After incuba-
tion, the immunoprecipitates were washed with LiCl wash buffer
(2.1% LiCl, 1.6% Tris–HCl, pH 7.4) and NaCl wash buffer (0.6% NaCl,
0.16% Tris–HCl, 0.03% EDTA, pH 7.4), respectively, and sedimented at
12,000 ×g for 1 min. The resulting pellets were then analyzed using
SDS-PAGE and Western blot (WB) analyses.
2.9. Prediction of full-length PLD2 structure: homology modeling
Based on the experimental data, a list of amino acid residues that is
key for PLD2 activities aswell as PLD2's interactionswith other proteins
was generated. This is shown in Table 1, and is used to assure the quality
of the predicted structures.
2.10. I-TASSER
Human PLD2's amino acid sequence was obtained from NCBI, and
submitted, to the protein structure prediction server, Iterative threading
assembly reﬁnement server (I-TASSER). I-TASSER threads the protein
Table 1
List of important amino acid residues in PLD2 and their functional role that are used in this paper as criteria for the PLD2 molecular modeling. These criteria are a summary of data from
both our lab and from other investigators, as listed in the references of the table. They present the starting experimental evidence used to test the model that, for example, certain amino
acids that interact with other signaling proteinswith knownmotifs (such as SH2 or SH3) need to be on the surface of PLD2 in order to bind to said proteins; or that certain alcohol-amino
acids (Ser, Thr, Tyr) need to be also exposed to the surface in order to be phosphorylated; or that the histidines on the two catalytic motifs should be in close spatial proximity.
Criteria based on experimental evidence that need to be applied to any predicted structure for validation.
Domain Amino acids Function References
Key sites of PLD2 PX domain Phe (F) 107,129
Leu (L) 166, 173
Arg (R) 172
GEF catalytic site [23,24]
Lys (K) 101, 102 and 103 Putative PKCζ binding sites [26]
Ser (S) 134 Putative Cdk5 phosphorylation site [35]
Pro (P) 145 and 148 Putative PLCγ binding sites [36]
Tyr (Y) 169 and 179 Grb2 binding sites [45]
Thr (T) 175 Putative Akt phosphorylation site [46]
Key sites Putative Rac2 binding sites of PLD2 PH domain Ile (I) 255–Val (V) 280 (CRIB1)
Ile (I) 306–His (H) 323 (CRIB2)
Putative Rac2 binding sites [38]
Tyr (Y) 296 Putative EGF-R phosphorylation site [39]
Other important sites of PLD2 His (H) 442–Gly (G) 457
(HEKLLVVDQVVAFLGG)
HKD motif 1 [10–16]
His (H) 756–Asn (N) 773
(HSKVLIADDRTVIIGSAN)
HKD motif 2 [20,40]
Tyr (Y) 415 Putative JAK3 phosphorylation site [39]
Tyr (Y) 511 Putative Src phosphorylation site [39]
Thr (T) 566 Putative PKC delta phosphorylation site [44]
Abbreviations
GEF guanine nucleotide exchange factor activity, PLC — phospholipase C, Cdk5 — Cyclin D kinase 5, PKC — protein kinase C, and Grb2— growth factor receptor binding protein.
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ble alignments. For unaligned regions, I-TASSER uses ab initiomodeling.
I-TASSER simulations can be run not only for the full chain, but also for
the separate domains [28]. Since I-TASSER-predicted full-length PLD2 is
principally comprised of random secondary structures (not shown), we
also obtained structures of domains separately. More than one solution
was obtained for individual domain predictions. One out of the many
solutions was chosen based on the criteria mentioned in Table 1.
These were docked pair-wise to obtain a group of candidate structures
of the complete protein. From this group, one ﬁnal model was chosen
visually, based on the criteria mentioned in Table 1.
2.11. Phyre-2
We also used the server, Phyre2 (protein homology/analogy recog-
nition engine), which is an improved version of Phyre. After creating
the proﬁle of non-redundant sequence, the secondary structure was
predicted. Using the proﬁle and model of secondary structure a full-
length 3D models were generated. The missing parts that arise during
the queues are determined by the loop librarymethod [26]. Finally, mo-
lecularmodeling and visualizationwere performed using the Swiss PDB
viewer (SPDBV). More than one solution was observed before ﬁnalizing
the ﬁnal structure. By visual inspection we concluded the PLD2 model
predicted by Phyre2 server meets most of the criteria listed in Table 1.
However, this model was not entirely energetically favorable as certain
amino acid conformations are not viable. These issues were ﬁxed by
manually perturbing the structure using SPDBV and minimizing the re-
sult using steepest decent and conjugate gradient methods. Finally, the
complete 3Dmodelwas energyminimizedwhich resulted in amodeled
structure, whichwas energetically favorable and consistentwith exper-
imental criteria listed in Table 1.
2.12. Molecular docking
The computer-simulated docking studies were performed using
both HEX 6.1 and Autodock Vina. In order to model the full-length
3D PLD2 structure from the different domains of PLD2 (obtained from
I-TASSER) as well as for docking two (PLD2/Rac2) the HEX [29] was
used. The structure of Rac2 was obtained from PDB database (PDB IDs
2W2T). HEX is a macromolecular docking program that takes into con-
sideration both shape and electrostatic charge. In predicting moleculardocking juxtapositions, it uses spherical polar Fourier (SPF) correlations
to accelerate the docking calculations. Inmany respects, this approach is
similar to conventional fast Fourier transform (FFT) docking methods,
which use Cartesian grid representations of the molecular shape and
electrostatic properties and translational FFTs to performdocking corre-
lations. The default docking control parameters of the HEX program
were used to arrive at 100 docked conformations [30]. In all the HEX
dockings, PLD2 was treated as receptor while the other protein partner
was treated as ligand.
2.13. Enzyme-substrate docking
For docking PLD2with its substrate 1, 2 di-octanoyl phosphatidyl cho-
line (PC8), PC8 structure was retrieved from the PDB database, ID: 2LYA.
PLD2 and the substrate 1,2-dioctanoyl-sn-glycero-3-phosphocholine
(PC8) were submitted to Autodock Vina [31]. Autodock Vina allows the
ligand to have ﬂexible/rotatable bonds. Docking with Autodock Vina
starts by deﬁning a search space or binding site in a restricted region of
the protein. The coordinates of Lys 444 zeta nitrogen lie between the
two catalytic Histidines (442 and 756) in our 3D model. Therefore, in
the present study, the receptor grid was generated using the coordinates
of Lysine 444. The resulting docking conformation was further visualized
using the PyMOL.
Using the same conditions, docking experiments were performed
with phosphatidyl ethanolamine (PE) and di-oleoyl phosphatidyl serine
(PS), in order to explain the ability and speciﬁcity of PLD2 towards PC.
Structures of PE and PS were retrieved from the PDB IDs 3B74 [32]
and 2LYB [33] respectively. To determine PIP2 binding sites on PLD2,
docking experiments were performedwith PLD2 and phosphatidyl ino-
sitol 4, 5-bisphosphate (PIP2) whose structure was retrieved from the
PDB ID, 3W68 [34].
2.14. Coordinates
Access to the full-length modeled structure created in this paper
can be found in the Supplementary data ﬁle “PLD2 coordinates of
3D structure model” with PDB that contains PDB coordinates in
text format. These coordinates can be used by any investigator to re-
construct the three-dimensional model we are presenting in this
study (Supplementary data).
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Data are presented as mean ± SEM. The difference between means
was assessed by the Single Factor Analysis of Variance (ANOVA) test.
Probability of p b 0.05 indicated a signiﬁcant difference.
3. Results and discussion
3.1. A 3D modeled structure of PLD2
The absence of a crystal structure for mammalian PLD2 hinders ad-
vances in the ﬁeld of PLD biology. To remedy this situation, we com-
bined modeling tools with biochemical evidence, such as substrate
accessible active site(s) and solvent accessible phosphorylation sites to
obtain a structural model. A compilation of criteria including consider-
able experimental evidence is shown in Table 1 [10,21,24,35–47].
These criteria are a summary of data from both our lab and from other
investigators, as listed in the references of the table. They present the
starting experimental evidence used to test themodel that, for example,
certain amino acids that interact with other signaling proteins with
known motifs (such as SH2 or SH3) need to be on the surface of PLD2
in order to bind to said proteins; or that certain alcohol-amino acids
(Ser, Thr, Tyr) need to be also exposed to the surface in order to be phos-
phorylated; or that the histidines on the two catalytic motifs should be
in close spatial proximity. Since the large majority of the criteria were
fulﬁlled with the initial model, we used it to further reﬁne a predicted
PLD2 structure.
The strategy we followed to obtain the full-length 3Dmodel of PLD2
is pictorially shown in Fig. 1A, which used two different protein predic-
tion programs algorithms, implemented by either I-TASSER or Phyre
and compared the resulting structures [28,48]. In either case, the scoring
that the structure solving programs provide had to be orthogonal with
the biological and biochemical data on Table 1. For example, energy
minimization was run only after a candidate structure has checked out
all requisites of Table 1.
3.2. PLD2 structure prediction— Phyre versus I-TASSER
When a full sequence was submitted to I-TASSER, the HKD motifs
were comparable to the crystallized bacterial HKD members. However,
a major part of the resulting structure was found to be randomwithout
the expected PX and PH domains. To remedy this, domain-wise struc-
tures were obtained from I-TASSER [28]. More than one solution was
obtained for each domain. Individual domains were chosen based on
the set criteria in Table 1. Next, using the program HEX, we docked
the globular domains of the possible solutions. The lowest energy
docking orientation was selected and the primary structures of the
fragments were linked to obtain the full-length modeled structure
(predicted at pH 7). In a complementary approach, the full-length
PLD2 sequence was submitted to the Phyre2 server for “Intensive”
modeling [48]. Multiple solutions were obtained out of which, the 3D
model structure that satisﬁed the set criteria in Table 1 and that with
the lowest energy score was selected. The conﬁdence of the resulting
model estimated by Phyre2 is summarized in Fig. 1B, which represents
the overall conﬁdence as a function of sequence. It is worth mentioning
that in the Phyre-predicted structure, 71% of the residues of PLD2 were
modeled at greater than 90% conﬁdence. Analysis of I-TASSER- and
Phyre-predicted PLD2 structures revealed that the criteria listed in
Table 1 are convincingly demonstrated to a larger extent in Phyre-
PLD2 and therefore we pursued the Phyre predicted model for PLD2
3D structure.
3.3. Reﬁning Phyre PLD2
The initial structural model obtained (that fulﬁlled criteria in
Table 1) was not energetically minimized. In several instances,sidechains were in untenable conformations such as steric hindrances
between some of the amino acid sidechains. Therefore, the model was
globally adjusted manually and through a combination of steepest de-
cent (1000 step) and conjugate gradient (300 step) energy minimiza-
tions implemented by SPDBV [49]. Bulk dielectric constants were used
for these calculations instead of explicit solvent molecules. All these
steps provided gave us a biochemically agreeable, energetically favor-
able, full-length PLD2 3D model. This model is shown in Fig. 2, where
active sites, protein binding sites and phosphorylation sites are labeled
in different colors (Fig. 2). Access to the full-length modeled structure
created in this paper can be found in the Supplementary data ﬁle
“PLD2 coordinates of 3D structure model” with PDB that contains PDB
coordinates in text format (Supplementary data).
3.4. A 3D comparison of PLD isoforms
Next, we sought to compare sequence as well as the modeled struc-
ture of PLD2 with other mammalian isoforms. First, we obtained the
predicted structures of PLD1 and PLD3-6 via Phyre2 server (energymin-
imizations were not performed for these structures). A multiple se-
quence alignment of PLD1 through 6 was performed using Clustal W,
following which we compared predicted 3D structures of PLD1, 3, 4
and 6 isoforms with our PLD2 structural model. It is known that PLD1
and 2 are the only mammalian isoforms that contain the regulatory
PX and PH domains. Fig. 3A and B shows the structural alignment of
the PX and PH domains of PLD1 and 2, respectively. The twoHKDmotifs
are spatially or three-dimensionally conserved among thePLD1 through
6 isoforms (Fig. 3C). Sequence alignments of the HKDmotifs of PLD iso-
forms is shown in Fig. 3D. Among the mammalian PLD isoforms, only
PLD1, 2 and 6 possess lipase activity. The lack of lipase activity in PLD3
and 4 cannot be attributed to the absence of PX and PH domains, since
PLD6 also lacks these domains and is still active upon dimerization.
Next, we wanted to compare the catalytic site of our PLD2 struc-
ture model, with that of streptomyces PLD that was crystallized
along with its substrate dibutyrylphosphatidyl choline (PDB ID:
1VOV) [50]. Fig. 3E and F shows the superimposed streptomyces
(white) and human PLD (green) active site residues, while Fig. 3G
shows sequence alignment of the same. These results indicate that
the active site residues of our predicted model for the PLD2 structure
ﬁts with the existing bacterial PLD crystal structure to a larger extent.
Speciﬁcally the orientation of the two key amino acids, histidines
442 and 756, those that play an important role in the phosphatidyl
choline hydrolysis are aligned.
3.5. Modeling of PLD2 complexed with phosphatidyl choline
Oncewe found that the active site residues superimpose,we decided
to test it by performing theoretical docking studies with its substrate
phosphatidylcholine (PC) andwith known protein interacting partners.
Examining these binding/interactions with the PLD2 model of Fig. 3
allowed us to test ourmodel in silico. Based on biochemical experimen-
tal data, the two histidines in the HKD motifs play an important role in
the catalytic conversion of PC to PA and choline [15,50,51]. We ﬁrst per-
formed lipase assays using variety of phosphatidylcholine species
(Fig. 4A) as well as other phospholipids (Fig. 4B). Results shown in
Fig. 4A indicate that PLD2-WT, but not PLD2-K758R can breakdown a va-
riety of PC species, including1,2-dioctanoyl-sn-glycero-3-phosphocholine
(PC8), 1,2-diarachidonoyl-sn-glycero-3-phosphate (AraPC) and 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC). Fig. 4B indicates that
C8-PC followed by DOPC, but neither PE nor PS serves as substrates
for this PLD2.
Next, to demonstrate phospholipid accommodation in PLD2's pre-
sumptive active site pocket of the 3D structural model of PLD2, initial
docking was performed with PLD2 and PC8 (from PDB ID: 2LYA) [33]
by employingAutodock vena [31]. PLD2was treated as receptor, where-
as PC8 as a small molecule ligand. The search space was centered at the
Overall confidence  as a function of sequence (Phyre)
Red  >90% confidence
Green  70-90% confidence 
Blue  50-70% confidence 
B
I-TASSER Phyre 2 ExtensiveProtein structure prediction servers
PLD2 primary sequence
                (NCBI) 
Putative PLD2 
 3D structure 
Submitted full-length  or 
submitted domain wise
(PX, PH and rest of the 
          sequence)
Obtained PX, PH and rest of the protein
Docking program: HEX  
PX1   with PH3
PX1    PH3                       Energy minimizations and 
adjusting untenable side chain conformations
Full-length 3D PLD2 structure model
Viewing tools (SPBDV, PyMol)
Full length PLD2













Phyre structure #2 
Phyre structure #9




Fig. 1. Phospholipase D2 is dual enzyme that bears guanine nucleotide exchange as well as lipase activity. (A) Self-explanatory schematic representing the strategy applied in this study to
obtain a PLD2 three-dimensional structure. Brieﬂy, PLD2 primary sequence was submitted to I-TASSER and Phyre2 Extensive protein prediction servers. Both the servers provided with
more than one solution, whichwere evaluated based on set criteria (the laboratory benchmarks) listed in Table 1. (B) Summary of conﬁdence in the structuralmodel of PLD2. Conﬁdence
in the PLD2 structure, as estimated by Phyre2, is displayed as a function of position in the proteins’ primary structure.
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the solutions derived by Autodock, the best scoring conformation was
presented in Fig. 4C and D, which shows PLD2's active site (Fig. 4C)
with the substrate PC8. The orientation of the key amino acids in the
active site is more clearly shown in Fig. 4D.3.6. Modeling of PLD2 with other phospholipids
Fig. 4B suggests that PLD2 while hydrolyzes PC, it is not able to hy-
drolyze other phospholipids, PE and PS. Therefore, we next wanted to
determine the speciﬁcity of PLD2's putative lipase active site pocket in
Fig. 2. PLD2 full-length structure model in three dimensions. (A, B) PLD2 3D structure in ribbon (A) and surface (B) modes. PX and PH domains of the protein are shown in yellow and gray,
respectively, while the rest of the protein is shown in blue. (Ci-Civ) Different snapshots (snapshot 2 is turned 50° X, snapshot 3 is turned 60° X, 125° Y, snapshot 4 is turned 70° anticlockwise Y,
30° Z from snapshot 1 as indicated in the Figure) of PLD2 3D structure model in surface mode indicating that the important amino acids that interact with the binding partners or subject to
posttranslational modiﬁcations are exposed to the solvent. Color code is as follows: Yellow— PX domain, Silver— PH domain, Cyan— Rest of the PLD2 bearing HKDmotifs, Magenta— Lipase
sites, Red— GEF sites, Orange— putative Phosphorylated sites, Brown— Putative lipid binding sites, Dark blue— PKC binding sites, Skyblue— PLC binding sites, Pink— CRIB1, and Purple —
CRIB2. Full access of this model can be found along with the paper in the website “PLD2 3D structure model”with PDB coordinates in text format (Supplementary data).
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formed docking with the phospholipids phosphatidylethanolamine
(PE) (PDB ID: 3B74) [32] and phosphatidylserine (PS) (PDB ID: 2LYB)
[33]. Panels E, F and G in Fig. 4 show PLD2's presumptive active site
docked with PC8, PE and PS. A closer observation of these results led
us to speculate that the choline group on PC is oriented outwards mak-
ing the choline release easy. In the case of both PE and PS, the head
groups are oriented inward into the presumptive active site pocket.
We propose that this makes the release of head group difﬁcult when
compared to that of PC, further affecting the hydrolysis. All this explains
the PLD2's ability to hydrolyze PC but not PE and PS (Fig. 4B). However
whether PS or PE can act as inhibitors of PLD2 is not clear, as these ex-
periments were performed with one substrate at a time (PS or PC orPE). In reality, other factors such as, afﬁnity of the enzyme (PLD2) to
the substrate and the amount of the substrate available and accessible
to the enzyme determine the formation of enzyme substrate complex
resulting in the product. Also additional in silico experiments with
PLD2 3D structure model with other possible phospholipid substrates
such as lysoPC, will give insight on PLD2's catalysis.
3.7. Mechanism of PLD2 lipase reaction, based on structural details
Based on our model of PLD2 3D structure and its docking with the
substrate PC8 (Fig. 4C–D), we propose the working model for human
PLD2 lipase activity (Fig. 5). The reaction could take place in three
steps that are explained as follows:
Fig. 3. Structural and sequence alignment of knownmammalian PLD isoforms. Based on themodel of Fig. 3 here are the depicted three dimension structure alignment of PLD1 (white) and
PLD2 (purple) PX (A) andPH (B) domains. (C) CatalyticHKDmotifs of PLD1–PLD6 showperfect alignment three dimensionally. (D) Sequence alignment of HKDmotifs of the knownmam-
malian PLD isoforms (PLD1, 2, 3, 4 and 6). (E, F) Superimposed active sites of streptomyces PLD (white) alongwith the substrate dibutyryl phosphatidylcholine (red) (PDB ID: 1VOV) and
human PLD2 structure model (green). (G) Sequence alignment of streptomyces PLD (170–465) and human PLD2 (446–775) with HKD motifs highlighted in cyan boxes.
75M. Mahankali et al. / Cellular Signalling 27 (2015) 69–811) With the help of the Aspartic acid 363, Histidine 442 (Ne) nucleo-
philically attacks the phosphate group on the substrate phosphatidyl
choline. This will form the tetrahedral phosphatidyl enzyme inter-
mediate as explained in [50,52].
2) The tetrahedral intermediate thus formed needs to be stabilized.
Histidine 756, Lysines in the HKD motif, Lysines 444 and 758
might play a crucial role in doing so. Lysines might have a role instabilizing the negative charges of the oxygens on the phosphate.
Mutation of lysine 758 completely inactivates the lipase.
3) Histidine 756, on the other handwill participate in the reaction pos-
sibly by donating a proton (Nd) leading to the release of choline.
Subsequently, with the help of Tyrosine 754, Histidine 756 activates
water. A second nucleophilic attack will take place where water will
nucleophilically attack the phosphate moiety. This will result in the
formation of phosphatidic acid (PA).
Fig. 4. PLD2 lipase catalytic site forms a groove that ﬁts the substrate PC. (A) Lipase assay of cells that were untransfected (white bars) or transfected with PLD2-WT (gray bars) or lipase
inactive mutant, PLD2-K758R (black bars) against 3 different phosphatidylcholines: 1,2-di-octanoyl (PC8), 1,2-di-arachidonoyl (Ar PC) or 1,2-dioleoylphosphatidylcholine (DOPC).
(B) Lipase activity performed with increasing concentrations of different phospholipids, PC8, DOPC, phosphatidylethanolamine (PE) and phosphatidylserine (PS) ranging from 0 to
3.5 mM. (C–D) Using the model depicted in Fig. 2, shown here is the lipase catalytic site groove of PLD2 with the substrate PC8 (C). (D) Orientation of key amino acids in the active
site of PLD2 towards the substrate PC8. (E, F) PLD2 HKD catalytic site with the PC8 (E) PE (F) and PS (G) in surface mode that shows the orientation of PC8 is in such a way that facilitates
choline release from the HKD groove while the same is not true in case of PE or PS.
76 M. Mahankali et al. / Cellular Signalling 27 (2015) 69–81Also the superimposition of bacterial PLD and human PLD2 (Fig. 3E)
indicates the conserved orientation of the key amino acids aswell as the
secondary structures. All this is in agreement with the mechanism of li-
pase action of bacterial PLD that was based on crystal structure [50,51].
These facts suggest that the presented model for PLD2 3D structure is
comparable to the bacterial PLD in terms of lipase reaction mechanism.
In addition, we are able to explain other existing biochemical ﬁndings
with the proposed 3D structure model.3.8. Modeling of PLD2 structure model with PIP2
It is well established that phosphatidyl inositol 4,5-bisphosphate
(PIP2) is one of the positive regulators of PLD2 [53]. Thereforewe sought
to determine the possible putative binding site for PIP2 on PLD2.
Biochemical data from the literature suggest that PIP2 might have
two binding sites on PLD2, one at PH domain and the other towards
the C-terminus [54]. In the same study they showed that Arginine 237
Fig. 5.Mechanism of PLD2 lipase activity. Based on the structural details obtained from Fig. 4, we propose the following steps in PC hydrolysis by PLD2. (A) Histidine 442 exerts a nucle-
ophilic attack onphosphatemoiety of PC,with thehelp of Aspartate 363. (B)His 756, Lysines 444 and758might be involved in stabilizing the tetrahedral intermediate. (C) In theﬁnal step,
Histidine 756 donates hydrogen to the tetrahedral intermediate and activates water, which then exerts a second nucleophilic attack, ultimately leading to the release of choline and
phosphatidic acid (PA) respectively.
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PLD2. In the same study they also suggested the possible PIP2 binding
regions binding in the C-terminal region [54]. PIP2 binding regions in
various proteins are not well deﬁned, but generally are comprised of
clusters of basic and aromatic amino acid residues. In a study by Sciorra
et al. [55], it was speculated that the region between 554 and 575 amino
acids inmouse PLD2might be a putative PIP2 binding region. This region
corresponds to 531–564 in human PLD2 (hPLD2). By mutational analy-
sis they showed that Arginines 554 (R553 in hPLD2) and 558 (R557 in
hPLD2) contribute in responding to PIP2 [55]. Howevermany other pos-
sible basic amino acids in that region,whichmight play a role in binding
to PIP2 binding cannot be ruled out. In order to determine if our model
can predict the new binding sites or if it can dock PIP2 to the proposed
binding sites, we performed docking experiments.
Docking was performed with PIP2 (PDB ID: 3W68) and our PLD2
structuremodel with the search site focused at PH domain and between
532 and 564 amino acids. Out of the solutions obtained, we chose three
solutions (Fig. 6). In each of these, polar inositol ring is oriented towards
the basic amino acid residue and the hydrophobic tail is oriented to-
wards aromatic amino acids, mostly tryptophan. The ﬁrst two solutions
are R236 and W238 (Fig. 6A,B), R557 and W563 (Fig. 6C,D) that weresuggested to be involved in PIP2 interaction. This information is in
consistent with our model for PLD2 3D structure. Fig. 6E,F on the other
hand, shows a novel putative PIP2 binding region in PH domain,
which involves R210, R212 and W233. This is a new site for PIP2 and
we provide here experimental conﬁrmation.
These results indicate that the polar region of PIP2 might interact
with the basic amino acid residues that are clustered and are surface
exposed. R210, 212, and 236 as well as K235 are all present as a cluster
in the near vicinity. The possibility of more than one PIP2 molecule
interacting with multiple basic amino acid clusters at the same time is
quite possible. In Fig. 6A, B, C and D, the docking conformation of PLD2
and PIP2 was shown in ribbon and surface modes. Along with the
basic amino acids, aromatic amino acids such as W might also play a
role by interacting with hydrophobic regions of PIP2.
Next, we wanted to explore the effect of the novel putative PIP2
binding mutants within the PH domain (R210 and R212) (Fig. 6E,F)
on lipase activity in the presence of PIP2. In order to do that a PLD2 dou-
ble mutant was made where R210 and R212 were mutated to alanine.
Intact cells or cell lysates overexpressing either PLD2-WT or PLD2-
R210/212A,were treatedwith increasing concentrations of PIP2 ranging
from 0 to 10 mM and lipase activity was determined. The results
78 M. Mahankali et al. / Cellular Signalling 27 (2015) 69–81presented in Fig. 6G and H indicate that PIP2 exerted a positive effect on
PLD-WT expressing cells in a dose-dependent fashion, as expected.
However, mutating R210 and R212, made PLD2 irresponsive to PIP2.
This indicates that R210/R212 within the PH domain of PLD2 is a
novel PIP2 biding site.
3.9. Protein interactions of PLD2: PLD2 and Rac2 molecular modeling
We next wanted to determine if our model could explain the
protein–protein interactions of PLD2. From previous studies in our lab,
we know that PLD2 and Rac2 interact with each other and in addition,
Rac2 inﬂuences PLD2 activity [38,56]. While this suggests that PLD2 is
an effector of Rac2, PLD2 acts as GEF for Rac2 and acts upstream [24].
Representative data showing the same is presented in Fig. 7A–B.
Fig. 7C shows our modeled PX domain (from Fig. 2) has PLD2-GEF cata-
lytic residues highlighted. From the three-dimensional model, it is obvi-
ous that residues F107, F129, L166, and L173might form a hydrophobicFig. 6. Prediction of PIP2 binding sites in the PH domain of PLD2. (A–F) Using the model de
ribbon (A, C and D) or surface (B, D and F)modes. Effect of PLD2 putative PIP2 binding site doub
lipase activity assay. Cell lysates (G) or intact cells (H)were treatedwith increasing concentrati
PLD2-R210/212A is irresponsive to PIP2.pocket, which we speculate might be involved in promoting nucleotide
exchange on Rac2.
The fact that Rac2 is both upstream affecting PLD2 and downstream
activated by PLD2 suggests the possibility of more than two binding
sites for Rac2 on PLD2. Taking into consideration these sets of facts,
we wanted to see if our PLD2 3D modeled structure was in agreement
with these experimental ﬁndings.We used the PLD2modeled structure
and performed HEX docking [57] with a ﬁrst Rac2 molecule (PDB id:
2W2T) [58]. From the several docking results that were generated, an
energetically favorable complex was chosen and docked with another
molecule of Rac2 (Fig. 7D, E). In agreement with the experimental
data, two Rac2 molecules are in close proximity to the PLD2-PX
and -PH domains.
We believe that the upstream Rac2 (shown in navy blue) that regu-
lates PLD2 via binding is in closer proximity to the CRIBmotifs (gray and
purple) of the PLD2-PH domain (Fig. 7D, E). On the other hand, the
PLD2-GEF catalytic site (green) is in close proximity to the downstreampicted in Fig. 2, shown here is the docking between PLD2 and PIP2 (PDB ID: 3W68) in
lemutant R210/212A on lipase activity in the presence of PIP2 determined by performing a
ons of PIP2 (0 to 10mM) and lipase assaywas performed. Unlike PLD2-WT, the PHmutant
Fig. 6 (continued).
79M. Mahankali et al. / Cellular Signalling 27 (2015) 69–81Rac2 (magenta) switch I (red) (Fig. 7D, E), which in conventional GEF
catalysis is usually perturbed by upstream GEFs. All this correlates
with the results of mutational analysis, which identiﬁed residues in
the PLD2-PX as GEF residues. Overall, PLD2-GEF activates Rac2, while
at the same time PLD2 is an effector protein for active Rac2-GTP.
3.10. Why is our model for PLD2 3D structure signiﬁcant?
Modeling experiments were performed using the ITASSER server
[28] and the Phyre2 [48] server. In both cases multiple models are
predicted and a “best”model is suggested. Groups that created each of
these servers used them in the recent Critical Assessment of Protein
Structure Prediction experiment (CASP 10). This experiment assesses
the ability of protein prediction algorithms and servers to predict
protein structures for proteins prior to their determination by X-ray
crystallography. From about 70 protein prediction servers created by
structural biomedical/bio computational scientists across the protein
structure prediction community, I-TASSER performed best and Phyre2
was in the upper 30% for prediction of three dimensional protein struc-
ture from primary sequences. An interesting ﬁnding in this experiment
was that these servers found the correct conformation much more
frequently among the top scoring 10 or so candidate models, but were
unable to correctly choose which of these was best.
This arguesﬁrst, that the predictionmethods used in this paperwere
among the very best at the current state of the art and second, that the
chances of selecting the best structural model are greatly improved by
supplementing largely energy-based scoring methods with alternative
information about a protein's structure. This information includes bio-
logical activity and information, for example molecule bindingproperties. Here we use just such biological information in conjunction
with sound structure prediction methodologies to identify models that
are consistent with known phospholipase biology and are heuristic,
suggesting both features of these enzymes and how these features can
be tested.
4. Conclusions
We present here a 3D modeled structure of PLD2 fully based on
biochemical and biological data and, in turn, explain several models of
how this enzyme interacts with other cell signaling proteins. Since a
3D structure for mammalian PLD has not previously been determined
(crystallography, NMR or otherwise) or predicted by any laboratory,
this contribution is ﬁrst as far as we can understand.
The model provides a structural basis that explains previously pub-
lished biological and biochemical ﬁndings by our and other labs. The
predicted modeled structure explains the active site, several motif ho-
mologies with other mammalian PLD isoforms and interaction with
known small molecule inhibitors. This is important since PLD2 has
been recently described as a tumorigenic and metastasis inducing pro-
tein. Finding good docking inhibitors will be important for understand-
ing and modulating pathology. The model also predicts what other
proteins should bind to PLD (we are giving the example of Rac2).
Further, it can be used to study the other enzymatic activity in PLD
that is, a GEF activity.
This study established a ﬁrm foundation for future bioinformatics-
based studies using full-length PLD2 as a model. While PLD2 activity
has been shown to be necessary for cellular processes, like leukocyte
chemotaxis and phagocytosis, and general cell migration. Deregulated
Fig. 7. PLD2 and Rac2 transmodulate each other. (A) GEF activity of PLD2-WT when compared to the GEF deﬁcient PLD2-F129Y or PLD2-R172C. (B) Lipase activity of PLD2-WT is signif-
icantly reduced in the presence of Rac2, suggesting a negative effect of Rac2 on PLD2. Activity of PLD2D263–266, which is deﬁcient in binding to Rac2, is rescued. (C) Modeled PLD2-PX
domain (ribbon) showingGEF site, and the key amino acid residues involved are listed. (D and E)Dockingmodel of PLD2 and Rac2 in ribbon (D) and surface (E)modes showing binding of
two Rac2molecules, one upstream (blue) (that has a negative effect on PLD2) and one downstream (magenta) (that is activated by PLD2-GEF activity). Color code: PX and PH domains of
PLD2 are in yellow and gray colors, respectively. Shown in aqua blue andmagenta are upstream and downstreamRac2molecules, respectively. In both Rac2molecules, red and blue colors
represent switch I and II, respectively. Labels are represented in same colors as that of each domain.
80 M. Mahankali et al. / Cellular Signalling 27 (2015) 69–81PLD2 levels were reported in several cancers such as breast, colorectal
and renal [59–63]. A recent publication from our own lab reported a
study in which the presence of PLD2 promoted the formation of
aggressive tumors in mice, while silencing PLD2 reduced tumor size[3]. All this suggests an increasing demand for the availability of
PLD2's 3D structure, which can then be used to design speciﬁc and efﬁ-
cient small molecule inhibitors or modulators that will regulate PLD2
activities/protein interactions.
81M. Mahankali et al. / Cellular Signalling 27 (2015) 69–81The predicted 3Dmodel of PLD2's structure reported here is in accor-
dance with the experimental evidence to a very large extent. From the
docking results with the known PLD2 binding partners presented in
the current study, we believe that exceptional modulators of PLD2 can
be developed more efﬁciently. The current model has also paved a
way to determine how PLD2 associates with themembranewhen stim-
ulated and the regulatory structural dynamics. Themodel should also
constitute the basis for the discovery of new enzymatic properties on
PLDs and new protein–protein associations with signaling proteins
or lipids.
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